{
    "nct_id": "NCT06554158",
    "official_title": "A Phase II Study of Post-Resection Radiation Dose and Treatment Site De-Escalation for Favorable Prognosis Human Papilloma Virus (HPV) or p16-Positive Oropharyngeal Cancer",
    "inclusion_criteria": "* Patients must be ≥ 18 years of age on the day of signing informed consent.\n* Patients must have a diagnosis of p16+ and/or HPV+ squamous cell carcinoma of the oropharynx (including base of tongue, glossotonsilar sulcus, tonsil, soft palate, vallecula, and/or posterior oropharyngeal wall).\n* pathologic stage T1-2 N1 M0 (AJCC 8th ed.) stage I or T3 N0-1 M0 stage II (AJCC 8th ed.) SCCA of the oropharynx, with ≤ 5 distinct nodes involved with tumor, ≤ 2mm ECE (extracapsular extension), ≥ 2mm surgical margins at primary site.\n* Karnofsky Performance Status (KPS) ≥ 60 within 8 weeks prior to registration.\n* neutrophil:lymphocyte ratio ≤ 5 within 8 weeks of registration.\n* hemoglobin count ≥ 10 within 8 weeks of registration. The patient may receive transfusion to reach this goal.\n* current non-smoker (at least 6 months) with ≤ 15 pack-year smoking history\n* start radiation within 8 weeks of resection (6 weeks preferable)\n* have undergone resection of the primary site with Transoral Surgery and neck dissection of at least the ipsilateral neck\n* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n* Ability to understand and willingness to sign a written informed consent.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Perineural invasion at primary site\n* Lymphovascular space invasion at primary site\n* Level 4 nodal involvement (even if resected)\n* Retropharyngeal nodal involvement (even if resected)\n* any intact, unresected disease\n* nodal disease pathologically invading adjacent neck musculature\n* Patients treated via an invasive, non-oral approach to the primary site, including jaw-splitting mandibulotomy with resection or lateral pharyngotomy\n* Prior history of malignancy diagnosed within 2 years prior to registration, except for nonmelanomatous skin cancer that has completed treatment and the patient is deemed as being disease-free or Gleason 6 prostate cancer that is undergoing active surveillance.\n* Patient with extracapsular extension (ECE) who has not had a biopsy of an ipsilateral neck lymph node that demonstrated squamous cell carcinoma",
    "miscellaneous_criteria": ""
}